Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation

Abstract

Nivolumab was associated with significant improvements in overall survival and progression-free survival, as compared with dacarbazine, among previously untreated patients who had metastatic melanoma without a BRAF mutation. (Funded by Bristol-Myers Squibb; CheckMate 066 ClinicalTrials.gov number, NCT01721772.).

Keywords

Affiliated Institutions

• Université Joseph Fourier FR
• Université Paris Cité FR
• Royal Prince Alfred Hospital AU
• Assistance Publique – Hôpitaux de Paris FR
• Helsinki University Hospital FI
• University Hospital Heidelberg DE
• Hôpital Saint-Louis FR
• Mater Health Services AU
• Aarhus University Hospital DK
• Royal Victoria Hospital CA
• Istituti di Ricovero e Cura a Carattere Scientifico IT
• University Hospital Cologne DE
• Centrum für Integrierte Onkologie DE
• Melanoma Institute Australia AU
• University of Siena IT
• Université Grenoble Alpes FR
• Hospital Clínic de Barcelona ES
• Cabrini Hospital AU
• Hôpital Saint-André FR
• Inserm FR
• Chris O’Brien Lifehouse AU
• Bristol-Myers Squibb (United States) US
• Greenslopes Private Hospital AU
• Institut Gustave Roussy FR
• BC Cancer Agency CA
• Centre Hospitalier Universitaire de Grenoble FR
• The Maria Sklodowska-Curie National Research Institute of Oncology PL
• Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" IT
• Hôpital Claude Huriez FR
• National Center for Tumor Diseases DE
• The University of Sydney AU
• Gallipoli Medical Research Foundation AU
• Laiko General Hospital of Athens GR
• Heidelberg University DE
• National and Kapodistrian University of Athens GR

Related Publications